Pharma — April 2023
-
Johnson & Johnson: Vil betale 8,9 mia. dollar i kræfterstatninger - NY
5.4.2023 06.34 • MarketWire •
Johnson & Johnson har foreslået en aftale om at forlige alle søgsmål relateret til medicinalkoncernens babypudder, der mistænkes for at have indeholdt det kræftfremkaldende mineral asbest.Det skriver Bloomberg News.
Forliget betyder, at Johnson & Johnson vil betale 8,9 mia. dollar for at slippe for mere end 40.000 søgsmål fra folk, der har benyttet selskabets talkumbaserede babypudder, og som
-
mener, at de af den årsag har udviklet forskellige kræftsygdomme.
Johnson & Johnson håber med forliget samtidig at en til formålet oprettet fond i fremtiden vil skulle håndtere eventuelle yderligere krav, således at selskabet herefter vil være økonomisk isoleret.
Et datterselskab under Johnson & Johnson vil i den forbindelse, ifølge planen, erklære sig konkurs for at skabe det juridiske fundament for fonden.
Tidligere har en dommer afvist at godkende en tilsvarende fremgangsmåde, men
-
forslaget indeholdt dengang ikke noget erstatningsbeløb til fordeling mellem sagsøgerne.
Hvis tilstrækkeligt mange af de mere end 40.000 sagsøgere accepterer forliget, vil det skulle gælde alle sagsøgere og dermed beskytte Johnson & Johnson mod nye retssager.
Johnson & Johnson har allerede tabt et dusin retssager forbundet med talkumpulveret, og selskabet blev i 2018 tvunget til at betale 2,5 mia. dollar i erstatning til 20 kvinder, som havde udviklet kræft i æggestokkene.
-
Aktien i Johnson & Johnson steg i tirsdagens eftermarked med 3,1 pct. I den ordinære handel vendte den også et mindre minus til et plus på 1,1 pct.
.\˙ MarketWire
-
Medicinalindustrien trak industriproduktionen op i februar https://www.proinvestor.com/investornyt/964022/medicinalindustrien-trak-industriproduktionen-op-i-februar
-
AstraZeneca : Lynparza Combination Improves PFS In Phase III Ovarian Cancer Trial https://www.proinvestor.com/investornyt/964027/astrazeneca-lynparza-combination-improves-pfs-in-phase-iii-ovarian-cancer-trial
-
Lundbeck/Jefferies: Kursmålet hæves forud for nyt om alzheimershåb -NY https://www.proinvestor.com/investornyt/966430/lundbeck-jefferies-kursmalet-haeves-forud-for-nyt-om-alzheimershab-ny
-
FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's disease agitation https://www.fiercepharma.com/pharma/fda-advisory-committee-backs-lundbeck-and-otsukas-rexulti-use-alzheimers-disease-agitation-9
-
Johnson & Johnson Stock: Bear vs. Bull https://www.proinvestor.com/investornyt/968419/johnson-amp-johnson-stock-bear-vs-bull
-
Merck & Co. agrees to buy Prometheus for $10.8 billion https://firstwordpharma.com/story/5728300
-
+75% i præmie.
-
Lundbeck: Giver FDA panels-ja et kursboost? https://www.proinvestor.com/boards/112071
-
Internationale aviser med Merck, GM og Lloyd's of London https://www.proinvestor.com/investornyt/968636/internationale-aviser-med-merck-gm-og-lloyds-of-london
-
Satsuma Pharma Agrees To Be Acquired By Shin Nippon Biomedical
https://www.proinvestor.com/investornyt/968639/satsuma-pharma-agrees-to-be-acquired-by-shin-nippon-biomedical -
Genentech : Tecentriq Combination Reduces Risk Of Cancer Returning In People With Liver Cancer https://www.proinvestor.com/investornyt/968640/genentech-tecentriq-combination-reduces-risk-of-cancer-returning-in-people-with-liver-cancer
-
AZN : IMFINZI-based Treatment Reduces Risk Of Disease Recurrence In Lung Cancer In Phase III Trial https://www.proinvestor.com/investornyt/968641/azn-imfinzi-based-treatment-reduces-risk-of-disease-recurrence-in-lung-cancer-in-phase-iii-trial
-
MorphoSys :
Long-term Data Show Prolonged, Durable Responses In DLBCL Patients Treated With Monjuvi https://www.proinvestor.com/investornyt/968633/morphosys-long-term-data-show-prolonged-durable-responses-in-dlbcl-patients-treated-with-monjuvi -
Lundbeck har milliardsællert inden for rækkevidde, vurderer børshus
https://www.proinvestor.com/investornyt/968646/lundbeck-har-milliardsaellert-inden-for-raekkevidde-vurderer-borshus -
GSK Plc: Gepotidacin Shows Non-inferiority To Nitrofurantoin In EAGLE-2 And EAGLE-3 Phase III Trials https://www.proinvestor.com/investornyt/968654/gsk-plc-gepotidacin-shows-non-inferiority-to-nitrofurantoin-in-eagle-2-and-eagle-3-phase-iii-trials
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind